Shukra Pharmaceuticals appointed Shivkant Dhakad as Company Secretary and Compliance Officer effective June 15, 2026. The Board of Directors approved the appointment during its meeting held on June 15, 2026. Dhakad brings 1.5 years of experience as an Assistant Company Secretary, with expertise in regulatory compliance, corporate filings, and board meeting coordination.

Concurrently, the Board accepted the resignation of Ms. Arpita Kabra from the post of Company Secretary and Compliance Officer, effective June 15, 2026. Kabra cited personal reasons and other professional commitments for her departure. The transition complies with Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with the SEBI Master Circular dated November 11, 2024.

Key Personnel Changes

The following table summarizes the changes in the company's secretarial and compliance leadership:

Dhakad, a member of the Institute of Company Secretaries of India (Membership No. A80894), confirmed his consent to act as Company Secretary and Compliance Officer pursuant to Section 203 of the Companies Act, 2013. He affirmed that he possesses the requisite qualifications and is not disqualified from holding the position under any applicable law.

Shukra Pharmaceuticals Ltd. has scheduled an Extra-Ordinary General Meeting (EGM) on July 6, 2026, at 12:00 p.m. via Video Conferencing to seek shareholder approval for the preferential allotment of 46,43,000 Convertible Equity Warrants at a revised price of ₹35.56 per warrant. The issue aggregates to ₹16,51,05,080 and targets the promoter category to raise capital. The price revision was necessitated by a delay in allotment following the original approval, requiring a fresh Special Resolution under Regulation 170(2) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

The Board of Directors approved the proposal on June 10, 2026. The warrants carry a right to subscribe to one Equity Share per warrant and have a tenure not exceeding 18 months from the date of allotment. The Board determined the Relevant Date for pricing as June 5, 2026, which is 30 days prior to the proposed EGM. The issue price is set at the higher of the previously approved ₹34 per warrant or the re-computed price of ₹35.56 per warrant. An amount equivalent to 25% of the original warrant issue price has already been received from the proposed allottees.

Ms. Rupal Patel, Practicing Company Secretary, was appointed as the Scrutinizer to ensure the voting process is conducted fairly. The meeting outcome was submitted to BSE Limited pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Preferential Allotment Details

Shareholding Pattern Post-Allotment